OICHARTS
8 AMThe 8 AM report →

ABCL

AbCellera Biologics Inc. Common Shares · XNAS · 131 sessions on record
$14.59▼ −0.23 · −1.6%from $14.82 the session before · Sep 30, 2026 close · end of day
Open
$14.78
High
$15.02
Low
$14.56
Day's range
$0.463.1% of the previous close
VWAP
$14.81close −1.5% from it
Volume, shares
4.86M1.06× the 20-session average
Traded, $
$72.0M
Trades
39.5K120 shares per trade
Previous close
$14.82−0.23 to the close
Market cap
$4.47Bat the close of Sep 30
Day range7% of the way up
$14.56$15.02
52-week range96% of the way up
$3.22 Apr 7$15.02 Sep 30

−2.8% from the high · +350% from the low

Options

No listed options on ABCL

Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close
131 sessions on file · from Mar 25
ABCL close over the last 126 sessions, with S&P 500 rebased to the first close3.3010.5417.78axis spans 439%S&P 500ABCLApr 1Jul 2Sep 30126 sessions from Apr 1 to Sep 30; the price axis spans 439 percent.

Quarterly results

consolidated · latest filed Aug 5, 2026 · SEC filings

Revenue $4.0M, −76% on a year earlier; profit −$55.4M in the Jun 2026 quarter, consolidated.

Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of ABCL on the consolidated basis with the market's move on the first session after each filing
QuarterRevenue $Revenue YoYProfit $Profit YoYEPS $Market on the day
Jun 2026filed Aug 5$4.0M▼ −76%−$55.4M—-0.18▲ +10.3%S&P 500 −0.2% · +10.5 pp
Mar 2026filed Aug 5$8.3M▲ +96%−$43.2M—-0.14▲ +10.3%S&P 500 −0.2% · +10.5 pp
Dec 2025filed Feb 24$44.9M▲ +790%−$8.9M—-0.03—not reached
Sep 2025filed Nov 6$9.0M▲ +38%−$57.1M—-0.19—not reached
Jun 2025filed Aug 5$17.1M▲ +130%−$34.7M—-0.12▲ +10.3%S&P 500 −0.2% · +10.5 pp
Mar 2025filed Aug 5$4.2M▼ −57%−$45.6M—-0.15▲ +10.3%S&P 500 −0.2% · +10.5 pp
Dec 2024filed Feb 27$5.0M▼ −45%−$34.2M—-0.11—not reached
Sep 2024filed Nov 6$6.5M▼ −1.4%−$51.1M—-0.17—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of ABCL on the consolidated basis, summed from the quarters filed
YearRevenue $Revenue YoYProfit $Profit YoYEPS $
FY25to Dec 2025$75.1M▲ +160%−$146.4M—-0.49
FY24to Dec 2024$28.8M▼ −24%−$162.9M—-0.55
FY23to Dec 2023$38.0M▼ −92%−$146.4M▼ −190%-0.51
FY22to Dec 2022$485.4M▲ +29%$158.5M▲ +3.3%0.50
FY21to Dec 2021$375.2M▲ +61%$153.5M▲ +29%0.48

Fundamentals

consolidated · filings to Jun 2026 · close $14.59 on Sep 30

5.0 times book value, revenue +100% over twelve months, market cap $4.47B.

Valuation
Market cap
$4.47Bon Sep 30
Price to earnings
—
Trailing EPS
$-0.54diluted · consolidated · four quarters to Jun 2026
Price to book
5.0consolidated · balance sheet to Jun 2026
Book value a share
$2.92consolidated · balance sheet to Jun 2026
Debt to equity
—
Return on equity
-17%trailing profit over average equity · consolidated
Dividend yield
—
Price to sales
68market cap over revenue, four quarters to Jun 2026
Shares outstanding
307Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
$66.2Mfour quarters to Jun 2026
Revenue growth, 12 months
▲ +100%against the twelve months before
Revenue 3-year CAGR
▼ −23%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
−$164.7Mfour quarters to Jun 2026
Profit growth, 12 months
—
Profit 3-year CAGR
—

Shareholding

quarter to Jun 2026 · SEC Form 13F

13F managers hold 74% of shares, BAKER BROS. ADVISORS LP the largest at 22%, Capital World Investors 8.9% and TWO SIGMA INVESTMENTS, LP 6.8%, as filed for the quarter to Jun 2026.

Held by 13F managers
74%of shares outstanding
Shares held
227M−7.6% on Mar 2026 among managers filing both
Managers holding
146130 a quarter earlier
Largest holder
22%BAKER BROS. ADVISORS LP
Largest 10 holderspercent of shares outstanding · change in shares against the previous quarter
Largest 13F holders of ABCL
ManagerSharesOf outstandingValueChange on quarter
BAKER BROS. ADVISORS LP66M22%$518.3M+5.47M
Capital World Investors27.2M8.9%$213.3M+455K
TWO SIGMA INVESTMENTS, LP20.9M6.8%$163.9M−249K
TD Waterhouse Canada Inc.19.1M6.2%$145.2M+6.98K
BANK OF AMERICA CORP /DE/12.3M4.0%$96.4M+6.28M
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC8.63M2.8%$67.8M−6.52M
ArrowMark Colorado Holdings LLC8.21M2.7%$64.4Munchanged
BlackRock, Inc.7.61M2.5%$59.7M−470K
Driehaus Capital Management LLC5.73M1.9%$45.0M−2.32M
TUDOR INVESTMENT CORP ET AL4.13M1.4%$32.4M−421K
Insider tradesSEC Forms 3, 4 and 5 · the latest 5

No open-market insider buying or selling in the last 90 days.

ABCL insider trades
InsiderTradeSharesPriceHeld after
Booth AndrewOfficerexercised · Jun 3, 2026250,000$0.19445,600
Montalbano John S.Directorbought · May 14, 202620,000$4.77241,000
Thermopylae Holdings Ltd.TenPercentOwnerbought · Feb 27, 202638,000$3.4456,134,097
Booth AndrewOfficerbought · Feb 27, 202642,600$3.42195,600
Thermopylae Holdings Ltd.TenPercentOwnerbought · Feb 26, 2026177,457$3.2756,096,097

Corporate actions

exchange records

No corporate action on record for ABCL yet.

Price history

131 sessions on record · to Sep 30 · end of day

ABCL is +29.3% over 20 sessions against the S&P 500's +0.1%, 2.8% below its 52-week high, realised volatility 59% annualised.

Returns against S&P 500longest window first · S&P 500 over the same sessions
Returns of the stock and S&P 500 over six windows, longest first
WindowFrom $ABCL %S&P 500 %Difference pp
120 sessionssince Apr 9$3.44▲ +320%▲ +12%+310
60 sessionssince Jul 7$7.69▲ +90%▲ +2.0%+88
20 sessionssince Sep 1$11.28▲ +29%▲ +0.11%+29
5 sessionssince Sep 23$12.31▲ +19%▼ −0.67%+19
1 sessionsince Sep 29$14.82▼ −1.5%▼ −0.21%−1.3
Averages of the closeclose against each average
5-session average
$13.74close +6.2% from it
20-session average
$12.21close +19% from it
50-session average
$10.21close +43% from it
Range and volumetrue range over 14 sessions · high to low over 20 · volume against the 20-session average
Average true range, 14
$0.805.5% of the close
Average day's range, 20
$0.845.8% of the close
Volume against 20 sessions
1.06×4.86M vs 4.61M average
Volatility and co-movement with S&P 500annualised from daily returns
Realised volatility, 20
59%≈ ±3.7% a session · moved more than that on 5 of 20
Realised volatility, 60
100%≈ ±6.3% a session · moved more than that on 13 of 60
Beta to S&P 500, 60
2.07moved with S&P 500 on 40 of 60 sessions
Up and down sessionscloses above and below the previous close
Last 20 sessions
13 up · 7 downof 20
Last 60 sessions
34 up · 25 downof 59
Best session, 250
▲ +35%Aug 10
Worst session, 250
▼ −12%Jun 5

Short-sale volume

25 sessions · to Sep 30, 2026

Short sales were 55% of reported volume on Sep 30, 2026, against 47% over the last 25 sessions.

Last 10 sessionsshare of the day's reported volume
ABCL daily short-sale volume
SessionShort volumeReported volumeShort share
Sep 30, 20261.21M2.22M54.6%
Sep 29, 20262.17M4.29M50.7%
Sep 28, 20261.87M3.37M55.3%
Sep 25, 2026638K1.31M48.8%
Sep 24, 2026654K1.92M34.0%
Sep 23, 2026743K1.97M37.7%
Sep 22, 2026907K2.13M42.5%
Sep 21, 20261.04M1.93M54.2%
Sep 18, 2026824K1.94M42.4%
Sep 17, 20261.91M3.87M49.4%

Filings

SEC EDGAR · newest first
ABCL SEC filings
FiledFormReport date
Aug 24, 20264Aug 24, 2026
Aug 18, 20264Aug 18, 2026
Aug 14, 20264Aug 14, 2026
Aug 14, 20264Aug 12, 2026
Aug 13, 20264Aug 11, 2026
Aug 13, 20268-KAug 12, 2026
Aug 13, 2026424B5—
Aug 11, 2026424B5—
Aug 10, 20268-KAug 10, 2026
Aug 7, 20268-KAug 7, 2026
Aug 5, 202610-QJun 30, 2026
Aug 5, 20268-KAug 5, 2026
Jul 29, 20268-KJul 29, 2026
Jul 6, 20268-KJun 30, 2026
Jul 6, 20264Jul 1, 2026
Jul 6, 20263Jun 30, 2026
Jul 6, 20264Jul 1, 2026
Jun 17, 20268-KJun 17, 2026
Jun 12, 20264Jun 11, 2026
Jun 12, 20268-KJun 11, 2026
Jun 12, 20264Jun 11, 2026
Jun 12, 20264Jun 11, 2026
Jun 11, 20263Jun 1, 2026
Jun 5, 20268-KJun 1, 2026
Jun 3, 20264Jun 3, 2026

About AbCellera Biologics Inc. Common Shares

SEC and exchange records
Company
AbCellera Biologics Inc. Common Shares
Exchange
XNAS
SEC CIK
1703057
Sessions on record
131
Price source
End of day · delayed
Computed
2 Oct, 02:27 am IST

OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.